Last updated: February 16, 2026
Overview of the Product and Market Context
NDC 46122-0671 is a branded formulation of Pertuzumab, marketed as Perjeta by Roche. It is a monoclonal antibody approved for HER2-positive breast cancer, including early-stage and metastatic indications. The drug's primary competitors include trastuzumab (Herceptin), ado-trastuzumab emtansine (Kadcyla), and newer biosimilars.
The HER2-targeted therapy market faces growing competition from biosimilar entries, which could influence pricing and market share over time. Current approval status covers breast and gastric cancers, with expanding indications potentially increasing demand.
Market Size and Growth Trajectory
The global breast cancer therapeutics market was valued at approximately USD 21 billion in 2022. HER2-positive segment represents an estimated USD 4 billion of this total, with monoclonal antibody therapies like Perjeta occupying a substantial share.
Projected annual growth rates for HER2-targeting therapies average 8-10% driven by increasing prevalence, expanded indications, and combination regimens.
Current Market Position
Perjeta's approval covers:
- Adjuvant therapy in early-stage HER2-positive breast cancer (FDA approved 2018)
- Metastatic HER2-positive breast cancer (initial approval 2012)
- Hereditary diffuse gastric cancer (under investigation/approvals)
Its sales reached USD 3.3 billion in 2022. Patent exclusivity pressures remain until 2027–2030, after which biosimilar entries are expected.
Pricing Analysis
As of 2023, list prices are approximately USD 8,300 per infusion, typically administered every 3 weeks. The average treatment course involves 18 infusions, totaling USD 149,400 per course.
| Parameter |
Value |
| List price per infusion |
USD 8,300 |
| Number of infusions per course |
18 |
| Total treatment cost |
USD 149,400 |
| Estimated wholesale acquisition cost (WAC) |
Slightly lower, around USD 7,500 per infusion |
Price adjustments consider payer negotiations, rebates, and competitive pressure. Biosimilar entries are priced 15-25% lower than originator, with initial biosimilar approvals in 2021–2022.
Price Projections
Short-term (next 1-2 years):
Prices will remain relatively stable due to patent exclusivity, with minor discounts reflecting payor negotiations (~10% off list price). The total treatment cost may decrease marginally to USD 134,460 with rebates.
Mid-term (3-5 years):
Post-patent expiration anticipated between 2027-2030, biosimilar competition may reduce list prices by 20-25%. Biosimilar versions could bring per-infusion prices down to approximately USD 6,250–6,600. The total course cost may fall to about USD 112,500–118,800.
Long-term (beyond 5 years):
Market share shifts from the originator to biosimilars may lower prices further. The consolidation of biosimilar options, potential pricing strategies to capture market share, and new indications could influence pricing dynamics.
Potential for Market Share Shift
- Original Perjeta sales are expected to peak before biosimilar competition gains traction.
- Biosimilars are projected to capture 60-70% of the HER2 therapy market within 3-4 years post-patent expiry.
- Market penetration depends on regulatory approvals, physician acceptance, and payer policies.
Pricing Influencers
- Patent expiration dates (anticipated 2027–2030)
- Biosimilar market penetration speed
- Reimbursement policies and formulary placements
- Clinical guidelines updates favoring or discouraging use of biosimilars
- Physician and patient acceptance
Regulatory and Policy Environment
The FDA and EMA support biosimilar development; biosimilar approval pathways are established. Payer pressures favor biosimilar utilization due to cost savings, which may influence market share more than regulatory constraints.
Summary of Key Price Projections
| Timeline |
Approximate Price per Infusion |
Total Course Cost |
Notes |
| 2023 (current) |
USD 8,300 |
USD 149,400 |
Patent protection in place; stable pricing |
| 2025-2026 |
USD 8,000 – 8,200 |
USD 144,000 – 147,600 |
Negotiated discounts; no biosimilar impact yet |
| 2027 (anticipated patent expiry) |
USD 6,250 – 6,600 |
USD 112,500 – 118,800 |
Biosimilar launches influence prices |
| 2028+ |
USD 5,500 – 6,000 |
USD 99,000 – 108,000 |
Market share shifts increase competition |
Key Takeaways
- The HER2-targeted therapy market for NDC 46122-0671 (Perjeta) is likely to experience reduced prices post-2027 due to biosimilar competition.
- Short-term pricing remains stable with modest discounts; long-term prices could decline by up to 25-35%.
- Market share is expected to shift toward biosimilars, which could accelerate pricing declines.
- Demand remains driven by expanding indications and increasing prevalence of HER2-positive cancers.
- Competitive dynamics, reimbursement policies, and healthcare provider acceptance will determine the actual pace of price decreases.
FAQs
-
When will biosimilars for Pertuzumab become available?
- Biosimilar applications for Pertuzumab have received approvals in several regions, with launches expected around 2024–2025, pending regulatory processes.
-
How much could biosimilars reduce Pertuzumab’s price?
- Biosimilars may lower prices by 15–25%, translating to treatment course savings of USD 20,000–40,000.
-
What is the expected market share of biosimilars after patent expiry?
- Biosimilars could capture 60–70% of the HER2 therapy market within 3–4 years post-expiry.
-
How will reimbursement policies impact future pricing?
- Payers favor biosimilars for cost savings, incentivizing their use and pressuring originator prices downward.
-
Are new indications expected to influence pricing strategies?
- Yes; expanded indications increase volume demand, which can affect pricing negotiations and market share strategies.
References
[1] IQVIA. "Global Oncology Market Insights," 2022.
[2] FDA. "Biosimilar Product Development and Approval," 2022.
[3] EvaluatePharma. "Global Oncology Market Trends," 2022.
[4] FDA. "Pertuzumab (Perjeta) Label," 2018.
[5] Lazare, M., et al. "Biosimilar Entry Impact on Oncology Drug Markets," Journal of Managed Care Pharmacy, 2022.
